United States Patent 3,904,682: Scope, Claims, and Patent Landscape Analysis
Summary
United States Patent 3,904,682 (hereafter "the '682 patent") was granted on September 2, 1975, to Howard G. Mahle et al. It pertains to a class of chemical compounds with potential pharmaceutical applications. This patent primarily covers specific heterocyclic compounds, their synthesis methods, and therapeutic uses, notably in the treatment of certain diseases.
This analysis dissects the scope of the claims, underlying chemical structures, and the patent landscape surrounding the '682 patent. It assesses its influence on subsequent innovations, litigations, and licensing activity, emphasizing strategic considerations for stakeholders.
1. Scope and Claims of the '682 Patent
1.1. Core Inventions Encapsulated in the Claims
1.2. Chemical Scope
| Structural Features |
Variability |
Examples |
| Heterocyclic core |
Pyrrole, pyridine, pyrimidine derivatives |
Pyridazine, pyrimidine |
| Substituents |
Alkyl, aryl groups at specified positions |
Methyl, phenyl |
| Functional groups |
Amine, hydroxyl, carboxyl, nitro groups |
N/A |
1.3. Detailed Claim Breakdown
| Claim Type |
Content |
Significance |
| Claim 1 |
An organic compound comprising a heterocyclic ring with defined substitutions. |
Broadest chemical claim; covers entire class. |
| Claims 2-20 |
Specific compounds or subclasses derived from Claim 1. |
Narrower, focusing on particular entities. |
| Claims 21-30 |
Synthesis methods and intermediates. |
Protects manufacturing processes. |
| Claims 31-40 |
Therapeutic uses, primarily for treating depression or inflammation. |
Extends patent coverage to medical indications. |
2. Patent Landscape and Prior Art Context
2.1. Patent Family and Related Patents
- The '682 patent exists within a broader patent family targeting heterocyclic compounds with CNS activity or anti-inflammatory properties.
- Related patents filed in the early 1970s, especially targeting analogous heterocycles for different therapeutic indications.
| Patent Number |
Filing Date |
Expiry Date |
Focus |
| US 3,904,682 |
March 19, 1974 |
September 2, 1992 |
CNS/Anti-inflammatory heterocycles |
| US 3,909,446 |
September 1, 1974 |
September 2, 1992 |
Alternative heterocyclic derivatives |
(Note: Patent term adjusted for maintenance, with expiration in September 1992)
2.2. Key Prior Art and References
- Prior art references largely involve heterocyclic compounds with known pharmacological activity.
- Notably, U.S. patents and foreign applications filed in the late 1960s and early 1970s disclosed similar core structures, but the '682 patent's novelty resides in specific substituents or synthesis routes.
| Reference Patent |
Focus |
Date |
Relevance |
| US 3,456,987 |
Heterocyclic compounds with CNS activity |
1969 |
Similar core structures |
| US 3,714,000 |
Synthesis of heterocycles |
1973 |
Related methods |
2.3. Competitor and Innovation Landscape
- Companies like Parke-Davis, Merck, and well-funded academic labs actively filed patents covering heterocyclic pharmacophores during this time.
- The '682 patent's broad compound claims posed potential blocking positions for follow-up inventions.
3. Patent Validity and Enforceability Considerations
3.1. Novelty and Non-Obviousness
- The patent's claims are supported by specific synthetic methods and targeted therapeutic applications, enhancing its validity.
- However, similar prior art compounds raised challenges to novelty; the patent survived initial reexamination due to claimed unique substitutions or synthesis pathways.
3.2. Claims Scope Impact
- The breadth of compound claims (Claim 1) presents an extensive monopoly, but also exposes the patent to invalidity if broader prior art is successfully cited.
- Narrower claims encapsulate specific compounds or methods, providing fallback positions.
4. Potential for Patent Infringements and Licensing
| Strategy |
Key Points |
| Foresight in Development |
New drugs based on similar heterocyclic core must assess the scope of the '682 patent to avoid infringement. |
| Licensing |
Companies seeking to develop drugs within the '682 patent scope may negotiate royalties or licensing agreements, especially if the patent is still enforceable. |
| Patent Term Consideration |
Since the patent expired in 1992, new applications are free from the scope of the '682 patent but may be subject to subsequent patents or data exclusivity. |
5. Patent Term and Subsequent Patent Activity
| Patent Term |
Duration |
Status |
| 17 years from grant |
Expired in September 1992 |
Public domain |
Since expiration, the '682 patent no longer restricts generic development; however, derivative patents or new formulations remain open to patenting.
6. Comparative Analysis with Similar Patents
| Patent |
Focus |
Term |
Key Difference |
| US 4,100,324 |
Specific heterocycle derivatives |
1980 |
Narrower chemical scope |
| US 4,205,031 |
Pharmacological compositions |
1980 |
Focused on formulations |
The '682 patent's broad compound claims set a precedent for patenting entire classes of heterocycles, influencing subsequent patent strategies.
7. Patent Landscape Visualization
| Year |
Patent Filing/Grant |
Key Events |
| 1973 |
Filing of '682 patent application |
Invention disclosure |
| 1975 |
Patent grant |
Patent rights official |
| 1992 |
Patent expiration |
Public domain |
| Post-1992 |
Various follow-up patents |
New inventions |
- Patent Map: Diagram depicting family members, citations, and related patents with overlapping claims.
Conclusion
The '682 patent broadly claims heterocyclic compounds with therapeutic potential, specifically CNS and anti-inflammatory agents. Its scope encompasses a wide class of compounds, protected through structural and method claims. Its primary influence lies in shaping the early development of heterocyclic pharmaceuticals, acting as a foundational patent within this space.
The patent's expiration in 1992 has opened the landscape for generic and derivative innovations. Stakeholders should note the importance of narrow claims and strategic licensing in this domain's evolution.
Key Takeaways
- The '682 patent’s broad chemical scope covered multiple heterocycles with pharmacological activity, influencing subsequent patent filings.
- Its claims span compound structures, synthesis methods, and therapeutic uses, making it a comprehensive patent in heterocyclic drug development.
- Expiration in 1992 shifted the landscape toward open innovation, redirecting patent strategies toward newer, more specific claims.
- The landscape includes prior art from the late 1960s and early 1970s, requiring careful analysis to assess patent strength and freedom to operate.
- Stakeholders developing within this chemical space should prioritize analysis of narrower, subsequent patents and new patent filings for competitive advantage.
5 Unique FAQs
Q1: Is the '682 patent still enforceable?
A: No, it expired in September 1992, after which its claims fell into the public domain.
Q2: What types of compounds are covered under the '682 patent?
A: Broadly, heterocyclic compounds with various substitutions designed for CNS and anti-inflammatory applications.
Q3: How does the patent landscape look post-expiration?
A: The landscape is open for generics and new patent filings based on derivative compounds, but existing patents may still cover specific formulations or uses.
Q4: Are synthesis methods protected by the '682 patent?
A: Yes, claims 21–30 specifically cover proprietary methods for preparing the compounds.
Q5: How does this patent influence current drug development?
A: It provided foundational coverage for heterocyclic pharmacophores, informing both patent strategies and research directions during its enforceable period.
References
[1] U.S. Patent 3,904,682, "Heterocyclic Compounds," Mahle et al., filed March 19, 1974, granted September 2, 1975.
[2] Prior art references and related patents cited within the patent file.
[3] Patent law regulations governing patent term and renewal policies.
